Education
About Us
Working with TipRanks
Follow Us
Q32 Bio Inc (QTTB)
:QTTB
QTTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.85 - $53.79
Previous CloseN/A
Volume113.57K
Average Volume (3M)247.43K
Market Cap
$23.14M
Enterprise Value$469.19M
Total Cash (Recent Filing)$248.13M
Total Debt (Recent Filing)$23.98M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 08, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.21
Shares Outstanding12,180,701
10 Day Avg. Volume212,787
30 Day Avg. Volume247,425
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.02
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap20.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit811.76
Enterprise Value/Ebitda-8.79
Forecast
1Y Price Target
$8.33Price Target Upside338.42% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Q32 Bio News
See All QTTB News
---
Bulls Say, Bears Say
Bulls Say
Corporate StrategyManagement believes current cash will provide runway into the second half of 2026, supporting ongoing and future trials.
Patient SatisfactionBempi is well tolerated and patients are satisfied with outcomes, indicating potential positive feedback from ongoing studies.
Bears Say
Financial ChallengesQTTB will likely need to raise cash to move bempi forward in alopecia areata, indicating financial challenges ahead.
---
Ownership Overview
0.59% Insiders
11.54% Mutual Funds
32.11% Other Institutional Investors
50.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
QTTB FAQ
What was Q32 Bio Inc’s price range in the past 12 months?
Q32 Bio Inc lowest stock price was $1.85 and its highest was $53.79 in the past 12 months.
What is Q32 Bio Inc’s market cap?
Q32 Bio Inc’s market cap is $23.14M.
When is Q32 Bio Inc’s upcoming earnings report date?
Q32 Bio Inc’s upcoming earnings report date is May 08, 2025 which is in 55 days.
How were Q32 Bio Inc’s earnings last quarter?
Q32 Bio Inc released its earnings results on Mar 11, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.53 by $0.37.
Is Q32 Bio Inc overvalued?
According to Wall Street analysts Q32 Bio Inc’s price is currently Undervalued.
Does Q32 Bio Inc pay dividends?
Q32 Bio Inc does not currently pay dividends.
What is Q32 Bio Inc’s EPS estimate?
Q32 Bio Inc’s EPS estimate is -1.23.
How many shares outstanding does Q32 Bio Inc have?
Q32 Bio Inc has 12,180,701 shares outstanding.
What happened to Q32 Bio Inc’s price movement after its last earnings report?
Q32 Bio Inc reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.53. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Q32 Bio Inc?
Currently, no hedge funds are holding shares in QTTB
---
Q32 Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.33 (338.42% Upside)
$8.33 (338.42% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 162.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.23%
12-Months-Change
Fundamentals
Return on Equity
-93.26%
Trailing 12-Months
Asset Growth
-25.36%
Trailing 12-Months
Company Description
Q32 Bio Inc
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.
---
QTTB Stock 12 Month Forecast
Average Price Target
$8.33
▲(338.42% Upside)
Technical Analysis
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering QTTB
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-86.22%
reiterated a buy rating 3 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -86.22% per trade.
---